(Q43525317)

English

A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

metastatic melanoma

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24178368%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

author name string

J F Grippo

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24178368%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

W Zhang

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24178368%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

D Heinzmann

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24178368%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

K H Yang

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24178368%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

J Wong

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24178368%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

A K Joe

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24178368%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

P Munster

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24178368%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

N Sarapa

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24178368%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

publication date

1 November 2013

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24178368%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

73

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24178368%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24178368%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

103-111

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24178368%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2324-5

21 January 2018

Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2324-5

21 January 2018

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2324-5

21 January 2018

Novel somatic mutations to PI3K pathway genes in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2324-5

21 January 2018

Melanoma biology and new targeted therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2324-5

21 January 2018

The RAF proteins take centre stage

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2324-5

21 January 2018

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2324-5

21 January 2018

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2324-5

21 January 2018

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2324-5

21 January 2018

Improved human bioavailability of vemurafenib, a practically insoluble drug, using an amorphous polymer-stabilized solid dispersion prepared by a solvent-controlled coprecipitation process

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2324-5

21 January 2018

Enterohepatic circulation: physiological, pharmacokinetic and clinical implications

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2324-5

21 January 2018

High-throughput oncogene mutation profiling in human cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2324-5

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43525317&oldid=2206101140"